Chronic Lymphocytic Leukemia International Prognostic Index
Risk Category* | Points | Treatment |
|---|---|---|
Low risk | (0–1 points) | No treatment recommended |
Intermediate risk | (2–3 points) | No treatment recommended, unless patient is symptomatic |
High risk | (4–6 points) | Treatment recommended, unless the patient is asymptomatic |
Very high risk | 7–10 points | Treatment with novel agents or in a clinical trial (preferred over chemotherapy) |
CLL-IPI Prognostic Factor Point Value: Age > 65 years = 1 point; CLL-IPI Prognostic Factor Point Value: Rai stage I-IV or Binet stage B-C = 1 point; Unmutated IGHV = 2 points; serum beta-2 microglobulin > 3.5 mg/L = 2 points; TP53 mutation or deletion 17p = 4 points. * For each CLL-IPI risk category, the overall survival (without treatment) at 5 years (p < 0.001 for all) is estimated to be: low-risk: 93% (95% CI 91-96); intermediate risk: 79% (95% CI 76-83); high risk: 63% (95% CI 58-69); very-high risk: 23% (95% CI 13-34) CLL = chronic lymphocytic leukemia; IGHV = immunoglobulin heavy chain variable region; IPI = international prognostic index. International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790. doi:10.1016/S1470-2045(16)30029-8 | ||